Form 4: Onyia Jude reports multiple insider transactions in NBIX

Rhea-AI Filing Summary

Onyia Jude reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 115,756 shares at a weighted average price of $124.02 per share. Following the reported transactions, holdings were 5,380 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Onyia Jude

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		M		2,560	A	$0	18,537	D
Common Stock	02/12/2026		F		1,426(1)	D	$123.1	17,111	D
Common Stock	02/13/2026		M		2,690	A	$0	19,801	D
Common Stock	02/13/2026		F		1,452(1)	D	$124.12	18,349	D
Common Stock	02/13/2026		M		2,717	A	$0	21,066	D
Common Stock	02/13/2026		F		1,466(1)	D	$124.12	19,600	D
Common Stock	02/13/2026		A		19,935(2)	A	$0	39,535	D
Common Stock	02/13/2026		F		10,755(1)	D	$124.12	28,780	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(3)	02/12/2026		M			2,560	(4)	(4)	Common Stock	2,560	$0	7,681	D
Restricted Stock Unit	(3)	02/13/2026		M			2,690	(5)	(5)	Common Stock	2,690	$0	5,380	D
Restricted Stock Unit	(3)	02/13/2026		M			2,717	(6)	(6)	Common Stock	2,717	$0	2,717	D
Stock Option	$124.12	02/13/2026		A		55,119		(7)	02/13/2036	Common Stock	55,119	$0	55,119	D
Restricted Stock Unit	(3)	02/13/2026		A		9,669		(8)	(8)	Common Stock	9,669	$0	9,669	D

Explanation of Responses:

1. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.

2. On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award.

3. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

4. This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,560 shares on February 12, 2026, and will vest as to 2,560 shares on February 12, 2027, 2,560 shares on February 12, 2028, and 2,560 shares on February 12, 2029, subject to the terms and conditions of the award.

5. This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,690 shares on February 13, 2025, vested as to 2,690 shares on February 13, 2026, and will vest as to 2,690 shares on February 13, 2027, and 2,690 shares on February 13, 2028, subject to the terms and conditions of the award.

6. This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,717 shares on February 13, 2024, vested as to 2,717 shares on February 13, 2025, vested as to 2,717 shares on February 13, 2026, and will vest as to 2,717 shares on February 13, 2027, subject to the terms and conditions of the award.

7. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

8. The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did NBIX Chief Scientific Officer Jude Onyia report?

Jude Onyia reported RSU vesting into common stock, tax-withholding share dispositions, and new equity awards. Activity included vested RSUs converting to shares, a performance-based share payout, a large stock option grant, and a new RSU grant with multi-year vesting schedules.

Were any Neurocrine Biosciences (NBIX) shares sold in this Form 4?

No open-market sales occurred. The filing states shares were withheld by Neurocrine Biosciences only to satisfy tax withholding requirements upon vesting of RSUs and PRSUs. Footnotes explicitly clarify that no shares were sold as part of these February 2026 transactions.

What performance-based shares did NBIX grant to Jude Onyia?

Onyia received 19,935 shares of Neurocrine common stock from PRSUs granted May 19, 2023. These units vested at 125% of target after performance metrics over a three-year period ending December 31, 2025 were certified effective February 13, 2026, triggering the enhanced payout.

What new stock option did NBIX grant to Jude Onyia in February 2026?

Neurocrine granted Onyia a stock option covering 55,119 shares of common stock with a stated exercise price of $124.12. One forty-eighth of the option becomes vested and exercisable on March 13, 2026, with an additional one forty-eighth vesting and becoming exercisable each month thereafter.

How will Jude Onyia’s 9,669 new RSUs from NBIX vest?

The 9,669 restricted stock units will vest in four equal annual installments. One quarter of the units vests on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030, subject to the award’s terms and conditions remaining satisfied.

What RSU vesting schedules for NBIX shares are described in the filing?

The filing details three RSU grants with annual vesting on February 12 or 13 each year. Tranches of 2,560, 2,690, and 2,717 shares vest across dates from 2024 through 2029 or 2027, reflecting ongoing multi-year equity compensation for Jude Onyia under previously granted awards.